Clinical Immunohaematology Laboratory, Queensland Institute of Medical Research, Brisbane, Australia.
Am J Transplant. 2011 May;11(5):888-95. doi: 10.1111/j.1600-6143.2011.03499.x.
Post-transplant lymphoproliferative disorder (PTLD) is a spectrum of major, life-threatening lymphoproliferative diseases occurring in the post-transplant setting. The majority of PTLD is of B-cell origin and is associated with several risk factors, the most significant being Epstein-Barr virus (EBV) infection. EBV's in vitro transforming abilities, distinctive latency, clonality within the malignant cells and response to targeted therapies implicate a critical role in the biology of PTLD. This minireview focuses on EBV-related PTLD pathogenesis, in particular the interplay between aspects of the EBV life cycle and latency with nonviral factors resulting in the wide spectrum of histology and clinical presentations encountered in PTLD. With the increased prevalence of transplantation a rise in the incidence of PTLD may be expected. Therefore the importance of laboratory and animal models in the understanding of PTLD and the development of novel therapeutic approaches is discussed.
移植后淋巴组织增生性疾病（PTLD）是一组主要的、危及生命的淋巴增生性疾病，发生于移植后。大多数 PTLD 为 B 细胞起源，并与几个危险因素相关，其中最重要的是 Epstein-Barr 病毒（EBV）感染。EBV 的体外转化能力、独特的潜伏期、恶性细胞内的克隆性以及对靶向治疗的反应，提示其在 PTLD 的生物学中起着关键作用。这篇小综述重点关注 EBV 相关的 PTLD 发病机制，特别是 EBV 生命周期和潜伏期中各个方面与非病毒因素之间的相互作用，导致了在 PTLD 中遇到的广泛的组织学和临床表现。随着移植的普及，PTLD 的发病率可能会上升。因此，实验室和动物模型在理解 PTLD 和开发新的治疗方法方面的重要性被讨论。
